Celldex Therapeutics Price to Sales Ratio 2010-2022 | CLDX
Historical PS ratio values for Celldex Therapeutics (CLDX) over the last 10 years. The current P/S ratio for Celldex Therapeutics as of March 23, 2023 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Celldex Therapeutics P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2023-03-24 |
36.56 |
|
727.06 |
| 2022-12-31 |
44.57 |
$0.05 |
886.35 |
| 2022-09-30 |
28.11 |
$0.02 |
1188.51 |
| 2022-06-30 |
26.96 |
$0.02 |
1469.81 |
| 2022-03-31 |
34.06 |
$0.10 |
331.65 |
| 2021-12-31 |
38.64 |
$0.12 |
332.33 |
| 2021-09-30 |
53.99 |
$0.24 |
228.54 |
| 2021-06-30 |
33.44 |
$0.25 |
133.83 |
| 2021-03-31 |
20.60 |
$0.17 |
119.27 |
| 2020-12-31 |
17.52 |
$0.31 |
56.13 |
| 2020-09-30 |
14.83 |
$0.25 |
60.39 |
| 2020-06-30 |
13.00 |
$0.26 |
49.19 |
| 2020-03-31 |
1.66 |
$0.30 |
5.45 |
| 2019-12-31 |
2.23 |
$0.26 |
8.45 |
| 2019-09-30 |
2.13 |
$0.37 |
5.73 |
| 2019-06-30 |
2.68 |
$0.42 |
6.34 |
| 2019-03-31 |
4.92 |
$0.65 |
7.54 |
| 2018-12-31 |
2.97 |
$0.97 |
3.06 |
| 2018-09-30 |
6.77 |
$1.20 |
5.62 |
| 2018-06-30 |
7.55 |
$1.57 |
4.80 |
| 2018-03-31 |
34.95 |
$1.75 |
19.97 |
| 2017-12-31 |
42.60 |
$1.50 |
28.34 |
| 2017-09-30 |
42.90 |
$1.38 |
31.16 |
| 2017-06-30 |
37.05 |
$1.25 |
29.56 |
| 2017-03-31 |
54.15 |
$1.01 |
53.84 |
| 2016-12-31 |
53.10 |
$1.02 |
52.26 |
| 2016-09-30 |
60.60 |
$1.02 |
59.66 |
| 2016-06-30 |
65.85 |
$0.84 |
78.28 |
| 2016-03-31 |
56.70 |
$0.96 |
58.93 |
| 2015-12-31 |
235.20 |
$0.84 |
279.01 |
| 2015-09-30 |
158.10 |
$0.81 |
194.19 |
| 2015-06-30 |
378.30 |
$0.84 |
448.90 |
| 2015-03-31 |
418.05 |
$0.61 |
684.79 |
| 2014-12-31 |
273.75 |
$0.60 |
455.10 |
| 2014-09-30 |
194.40 |
$0.47 |
413.32 |
| 2014-06-30 |
244.80 |
$0.47 |
524.13 |
| 2014-03-31 |
265.05 |
$0.39 |
687.16 |
| 2013-12-31 |
363.15 |
$0.80 |
451.26 |
| 2013-09-30 |
531.45 |
$1.64 |
324.92 |
| 2013-06-30 |
234.15 |
$2.24 |
104.57 |
| 2013-03-31 |
173.70 |
$2.73 |
63.53 |
| 2012-12-31 |
100.65 |
$2.97 |
33.86 |
| 2012-09-30 |
94.50 |
$2.95 |
32.05 |
| 2012-06-30 |
77.63 |
$2.97 |
26.17 |
| 2012-03-31 |
76.35 |
$3.24 |
23.60 |
| 2011-12-31 |
39.00 |
$3.68 |
10.58 |
| 2011-09-30 |
34.28 |
$20.51 |
1.67 |
| 2011-06-30 |
53.25 |
$20.84 |
2.56 |
| 2011-03-31 |
60.30 |
$21.44 |
2.81 |
| 2010-12-31 |
61.80 |
$22.02 |
2.81 |
| 2010-09-30 |
60.00 |
$7.86 |
7.64 |
| 2010-06-30 |
68.40 |
$10.53 |
6.49 |
| 2010-03-31 |
92.10 |
$11.68 |
7.88 |
| 2009-12-31 |
70.05 |
$13.46 |
5.20 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.714B |
$0.002B |
|
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
|
